$111 Million is the total value of Opus Point Partners Management, LLC's 63 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIB | PROSHARES TR | $7,993,000 | +14.7% | 130,500 | 0.0% | 7.17% | +12.3% | |
| BMY | BRISTOL MYERS SQUIBB CO | $5,737,000 | +14.4% | 90,000 | 0.0% | 5.15% | +12.0% | |
| XBI | SPDR SERIES TRUSTs&p biotech | $5,627,000 | +12.2% | 65,000 | 0.0% | 5.05% | +9.8% | |
| MRK | MERCK & CO INC | $5,359,000 | -0.1% | 83,700 | 0.0% | 4.81% | -2.2% | |
| ALXN | ALEXION PHARMACEUTICALS INCcall | $4,910,000 | +15.3% | 35,000 | 0.0% | 4.40% | +12.9% | |
| IBB | ISHARES TRnasdaq biotech | $4,170,000 | +7.6% | 12,500 | 0.0% | 3.74% | +5.4% | |
| AZN | ASTRAZENECA PLCsponsored adr | $4,066,000 | -0.6% | 120,000 | 0.0% | 3.65% | -2.7% | |
| PFE | PFIZER INC | $4,009,000 | +6.3% | 112,300 | 0.0% | 3.60% | +4.1% | |
| BMY | BRISTOL MYERS SQUIBB COcall | $2,869,000 | +14.4% | 45,000 | 0.0% | 2.57% | +12.0% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $2,436,000 | -5.8% | 60,000 | 0.0% | 2.19% | -7.8% | |
| MTD | METTLER TOLEDO INTERNATIONAL | $2,250,000 | +6.4% | 3,594 | 0.0% | 2.02% | +4.2% | |
| RXDX | IGNYTA INC | $2,106,000 | +19.3% | 170,500 | 0.0% | 1.89% | +16.8% | |
| LABU | DIREXION SHS ETF TRsp biotch bl new | $1,368,000 | +35.6% | 16,002 | 0.0% | 1.23% | +32.8% | |
| LLY | LILLY ELI & COcall | $1,283,000 | +3.9% | 15,000 | 0.0% | 1.15% | +1.8% | |
| LOXO | LOXO ONCOLOGY INC | $1,271,000 | +14.8% | 13,800 | 0.0% | 1.14% | +12.4% | |
| CLVS | CLOVIS ONCOLOGY INC | $1,236,000 | -12.0% | 15,000 | 0.0% | 1.11% | -13.8% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $1,098,000 | +21.3% | 100,000 | 0.0% | 0.98% | +18.8% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $1,004,000 | +4.1% | 40,000 | 0.0% | 0.90% | +2.0% | |
| PCRX | PACIRA PHARMACEUTICALS INC | $939,000 | -21.3% | 25,000 | 0.0% | 0.84% | -23.0% | |
| GILD | GILEAD SCIENCES INCcall | $810,000 | +14.7% | 10,000 | 0.0% | 0.73% | +12.4% | |
| AXSM | AXSOME THERAPEUTICS INC | $741,000 | +1.0% | 133,500 | 0.0% | 0.66% | -1.0% | |
| TSRO | TESARO INC | $646,000 | -7.6% | 5,000 | 0.0% | 0.58% | -9.4% | |
| ADMS | ADAMAS PHARMACEUTICALS INC | $635,000 | +21.0% | 30,000 | 0.0% | 0.57% | +18.5% | |
| MDCO | MEDICINES CO | $519,000 | -2.4% | 14,000 | 0.0% | 0.47% | -4.3% | |
| AKBA | AKEBIA THERAPEUTICS INC | $413,000 | +36.8% | 21,009 | 0.0% | 0.37% | +33.9% | |
| SNR | NEW SR INVT GROUP INC | $383,000 | -9.0% | 41,850 | 0.0% | 0.34% | -10.9% | |
| HRTX | HERON THERAPEUTICS INC | $256,000 | +16.4% | 15,874 | 0.0% | 0.23% | +13.9% | |
| AVXS | AVEXIS INC | $242,000 | +18.0% | 2,500 | 0.0% | 0.22% | +15.4% | |
| REPH | RECRO PHARMA INC | $227,000 | +28.2% | 25,231 | 0.0% | 0.20% | +25.9% | |
| CFRX | CONTRAFECT CORP | $167,000 | -23.4% | 150,000 | 0.0% | 0.15% | -25.0% | |
| SCYX | SCYNEXIS INC | $161,000 | +35.3% | 66,608 | 0.0% | 0.14% | +32.1% | |
| PGNX | PROGENICS PHARMACEUTICALS IN | $160,000 | +8.1% | 21,782 | 0.0% | 0.14% | +5.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.